Which endpoints does published GHK-Cu literature most commonly measure? A structured reference on the in-vitro research 'benefits' as reported in cell culture.
In the research literature, GHK-Cu 'benefits' refers strictly to measured in-vitro endpoints in cell and tissue cultures — never to human outcomes. The most-cited endpoints are grouped below.
- Upregulation of collagen I, III and elastin transcripts in fibroblast culture.
- Increased SOD and metallothionein expression.
- Increased decorin and glycosaminoglycan synthesis in dermal-model culture.
- Angiogenic-marker upregulation in wound-model in-vitro literature.
- MMP/TIMP balance modulation reported in published dermal-culture studies.
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
